873055-22-2 Usage
Description
6-Amino-1H-Indole-4-Carboxylic Acid Ethyl Ester is a chemical compound that belongs to the class of indole derivatives. It is a derivative of 6-aminoindole and is commonly used in the synthesis of various organic compounds.
Used in Pharmaceutical Industry:
6-Amino-1H-Indole-4-Carboxylic Acid Ethyl Ester is used as a building block for the development of potential drug candidates due to its unique chemical structure and properties.
Used in Medicinal Chemistry and Drug Discovery:
6-Amino-1H-Indole-4-Carboxylic Acid Ethyl Ester is used as a building block for the synthesis of heterocyclic compounds, which have applications in medicinal chemistry and drug discovery.
Used in Organic Electronics and Materials Science:
6-Amino-1H-Indole-4-Carboxylic Acid Ethyl Ester has potential applications in the field of organic electronics and materials science.
Check Digit Verification of cas no
The CAS Registry Mumber 873055-22-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,3,0,5 and 5 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 873055-22:
(8*8)+(7*7)+(6*3)+(5*0)+(4*5)+(3*5)+(2*2)+(1*2)=172
172 % 10 = 2
So 873055-22-2 is a valid CAS Registry Number.
873055-22-2Relevant articles and documents
Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
-
, (2015/09/22)
The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
-
, (2012/04/23)
The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
